EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of EphA2 siRNA in treating patients
with solid tumors that have spread to other places in the body and usually cannot be cured or
controlled with treatment (advanced) or have come back after a period of improvement
(recurrent). EphA2-targeting DOPC-encapsulated siRNA may slow the growth of tumor cells by
shutting down the activity of a gene that causes tumor growth.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Cancer Prevention Research Institute of Texas National Cancer Institute (NCI)